NCT07169682View on ClinicalTrials.gov

Effects of IL17/23 Inhibitors on Markers of Subclinical Atherosclerosis in Patients With Psoriasis

CompletedOBSERVATIONAL
Enrollment

66

Participants

Timeline

Start Date

September 1, 2021

Primary Completion Date

September 30, 2024

Study Completion Date

September 30, 2024

Conditions
PsoriasisCardiovascular DiseaseAtherosclerosis
Interventions
DRUG

interleukin 17 inhibitor

52 weeks

DRUG

interleukin-23 inhibitor

52 weeks

DRUG

conventional systemic agent or apremilast

52 weeks

Trial Locations (1)

17124

Andreas Sygros Hospital, Athens

All Listed Sponsors
collaborator

Andreas Syggros Hospital of Venereal and Dermatological Diseases

OTHER

lead

National and Kapodistrian University of Athens

OTHER

NCT07169682 - Effects of IL17/23 Inhibitors on Markers of Subclinical Atherosclerosis in Patients With Psoriasis | Biotech Hunter | Biotech Hunter